Embecta Corp (EMBC) is a leading medical technology company specializing in innovative insulin delivery systems aimed at enhancing diabetes management. Born from a spin-off of Becton, Dickinson and Company, Embecta provides a comprehensive portfolio of advanced products, including cutting-edge insulin pens and syringes tailored to improve patient outcomes. With a robust focus on operational excellence and customer satisfaction, Embecta is well-positioned to capitalize on growth opportunities in the rapidly expanding diabetes care market, strengthening its leadership in this vital sector.
| Revenue (TTM) | $1.02B |
| Gross Profit (TTM) | $595.10M |
| EBITDA | $281.50M |
| Operating Margin | 23.70% |
| Return on Equity | 0.00% |
| Return on Assets | 12.20% |
| Revenue/Share (TTM) | $17.33 |
| Book Value | $-10.81 |
| Price-to-Book | 2.61 |
| Price-to-Sales (TTM) | 0.32 |
| EV/Revenue | 1.564 |
| EV/EBITDA | 5.99 |
| Quarterly Earnings Growth (YoY) | -53.70% |
| Quarterly Revenue Growth (YoY) | -8.10% |
| Shares Outstanding | $56.66M |
| Float | $54.77M |
| % Insiders | 2.02% |
| % Institutions | 92.39% |
Volatility is currently contracting
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP , a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain directors and officers of Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC).
In September, embecta will participate in the Wells Fargo 2026 Healthcare Conference and the J.P. Morgan 4th Annual Nashville Healthcare Conference 2026.
New York, New York--(Newsfile Corp. - August 26, 2026) - Bernstein Liebhard LLP, a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain directors and officers of Embecta Corp. ("Embecta" or the "Company") (NASDAQ: EMBC). The investigation seeks to determine whether the Company's leadership fulfilled its obligations to shareholders and whether legal remedies may be available.
Embecta offers a compelling deep value opportunity, trading at a P/E below 3x and free cash flow yield above 50%. Despite slightly declining sales and excessive debt, EMBC's high gross margins (59.6%) and market leadership position support a bullish 12-month target of $8-10 per share. Technical momentum has turned positive, with insider buying and extended short interest setting up the potential for a sharp rebound if fundamentals stabilize.
New York, New York--(Newsfile Corp. - August 18, 2026) - Bernstein Liebhard LLP, a nationally recognized investor rights law firm, announces that it is investigating potential breaches of fiduciary duty by certain directors and officers of Embecta Corp. ("Embecta" or the "Company") (NASDAQ: EMBC). The investigation seeks to determine whether the Company's leadership fulfilled its obligations to shareholders and whether legal remedies may be available.
A securities fraud class action lawsuit has been filed on behalf of Embecta investors after its stock plummeted over 57% because Embecta allegedly misled investors regarding the strength of its insulin pen needle product category. NEW YORK, Aug. 18, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Embecta Corp. (NASDAQ:EMBC) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.
NEW YORK--(BUSINESS WIRE)---- $EMBC #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC) and reminds investors of the August 17, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has.
NEW YORK, Aug. 17, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Embecta Corp. (NASDAQ: EMBC) between November 25, 2025 and May 4, 2026, inclusive (the "Class Period"), of the important August 17, 2026 lead plaintiff deadline. So what: If you purchased Embecta common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
NEW YORK, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Embecta Corp. (NASDAQ: EMBC) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Embecta securities between November 25, 2025 and May 4, 2026, both dates inclusive (the “Class Period”).
NEW YORK, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Embecta Corp. (NASDAQ:EMBC) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in Embecta, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/embecta-class-action-lawsuit.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on EMBC and any ticker you trade — then tracks every position and per-strategy win rate.
